- Stocks
- Pharma & Healthcare
- Unichem Laboratories
Unichem Laboratories share price
NSE: UNICHEMLABPharma & HealthcareDrug Manufacturers - Specialty & Generic
Unichem Laboratories at a glance
Unichem Laboratories (NSE: UNICHEMLAB) closed at ₹495.95 on 22 Oct 2026, down 3.51% on the day. With a market capitalisation of ₹3,492 Cr, it ranks 917th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 13.8× trailing earnings, against a return on equity of 9.3% in FY26. Over the past year the share price has risen 5.5%. Its 52-week range is ₹278.20 (30 Mar 2026) to ₹687.20 (9 Jul 2026); the last close is 27.8% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹575 Cr (−2.1% year on year) and net profit ₹11 Cr (−79.4%), on a consolidated basis. Promoters held 70.22% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹3,492 CrRank 917 on NSE
- P/E (trailing)
- 13.8×
- Price to book
- 0.76×FY26
- EPS (TTM)
- ₹35.91to Q4 FY26
- ROE
- 9.3%FY26
- ROCE
- 4.3%FY26
- Debt to equity
- 0.17FY26
- Net profit margin
- 11.5%FY26
- Book value / share
- ₹386.00FY26
- 52-week high
- ₹687.209 Jul 2026
- 52-week low
- ₹278.2030 Mar 2026
- 1-year return
- +5.5%
- RSI (14-day)
- 38
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −3.51% | −4.6% | −9.4% | −6.3% | +5.5% |
Unichem Laboratories quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹446 Cr | ₹462 Cr | ₹533 Cr | ₹587 Cr | ₹527 Cr | ₹579 Cr | ₹521 Cr | ₹575 Cr |
| Revenue YoY | +5.5% | +11.2% | +22.7% | +36.0% | +18.0% | +25.3% | −2.2% | −2.1% |
| Net profit | ₹9 Cr | ₹30 Cr | ₹58 Cr | ₹53 Cr | −₹10 Cr | −₹12 Cr | ₹264 Cr | ₹11 Cr |
| Net profit YoY | — | — | −31.1% | — | −213.1% | −139.0% | +356.9% | −79.4% |
| Net margin | 2.1% | 6.6% | 10.9% | 9.0% | −2.0% | −2.1% | 50.7% | 1.9% |
| EPS | ₹1.31 | ₹4.34 | ₹8.22 | ₹7.52 | −₹1.49 | −₹1.69 | ₹37.54 | ₹1.55 |
Unichem Laboratories financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,235 Cr | ₹1,270 Cr | ₹1,343 Cr | ₹1,705 Cr | ₹2,111 Cr | — |
| Operating profit | ₹52 Cr | ₹23 Cr | −₹138 Cr | −₹4 Cr | ₹155 Cr | — |
| Net profit | ₹35 Cr | ₹34 Cr | −₹164 Cr | −₹70 Cr | ₹138 Cr | — |
| EPS (₹) | ₹5.00 | ₹5.00 | −₹29.00 | −₹10.00 | ₹20.00 | — |
| Cash from operations | ₹33 Cr | −₹260 Cr | −₹85 Cr | ₹17 Cr | −₹7 Cr | — |
| Total debt | ₹0 Cr | ₹89 Cr | ₹64 Cr | ₹38 Cr | ₹61 Cr | ₹39 Cr |
| Shareholders' equity | ₹2,557 Cr | ₹2,618 Cr | ₹2,435 Cr | ₹2,362 Cr | ₹2,451 Cr | ₹2,717 Cr |
Unichem Laboratories shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% |
| Foreign institutions | 0.98% | 0.98% | 1.00% | 0.99% | 1.00% | 0.90% |
| Domestic institutions | 11.32% | 10.92% | 10.75% | 10.74% | 10.63% | 10.46% |
| Non-institutions | 17.48% | 17.88% | 18.03% | 18.05% | 18.15% | 18.42% |
Unichem Laboratories vs peers
The listed Pharma & Healthcare companies nearest to Unichem Laboratories by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| GUFICBIOGufic Biosciences | ₹401.55 | +3.43% | +9.9% | ₹4,027 Cr | 62.7 | — |
| GUJTHEMGujarat Themis Biosyn | ₹365.70 | +4.88% | −11.9% | ₹3,985 Cr | 85.4 | — |
| UNICHEMLABUnichem Laboratories | ₹495.95 | −3.51% | +5.5% | ₹3,492 Cr | 13.8 | — |
| AARTIDRUGSAarti Drugs | ₹381.15 | −1.51% | −24.5% | ₹3,479 Cr | 17.9 | — |
| SOLARASolara Active Pharma Sciences | ₹650.75 | +1.48% | +11.8% | ₹3,140 Cr | — | — |
| INDSWFTLABInd-Swift Laboratories | ₹347.05 | +1.92% | +240.9% | ₹3,018 Cr | 71.6 | — |
| ADVENZYMESAdvanced Enzyme Technologies | ₹265.45 | +1.39% | −13.2% | ₹2,972 Cr | 17.6 | — |
Ask anything about Unichem Laboratories
Pivot answers on the live chart with evidence you can check, and tests strategies against UNICHEMLAB's own history. Try: “Why has UNICHEMLAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on UNICHEMLAB over five years” · “Compare UNICHEMLAB with GUFICBIO on margins and valuation”
Frequently asked questions about Unichem Laboratories
What is the share price of Unichem Laboratories today?
Unichem Laboratories (NSE: UNICHEMLAB) last closed at ₹495.95 on 22 Oct 2026. Its 52-week high is ₹687.20 and its 52-week low is ₹278.20.
What is the market cap of Unichem Laboratories?
Unichem Laboratories' market capitalisation is ₹3,492 Cr (₹3,492 Cr) at the 22 Oct 2026 close, ranking 917th among the NSE companies Pivot tracks.
What is the P/E ratio of Unichem Laboratories?
Unichem Laboratories trades at a trailing P/E of 13.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 62.7.
What is the ROE and ROCE of Unichem Laboratories?
Return on equity was 9.3% in FY26 and return on capital employed was 4.3% in FY26 (consolidated figures).
Is Unichem Laboratories a debt-free company?
No. Unichem Laboratories' debt-to-equity ratio was 0.17 in FY26, with total debt of ₹39 Cr.
What were Unichem Laboratories' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Unichem Laboratories reported revenue of ₹575 Cr, −2.1% year on year, and net profit of ₹11 Cr, −79.4% year on year.
How has Unichem Laboratories stock performed over the last year?
Unichem Laboratories' share price has risen 5.5% over the past year, −6.3% over three months and −9.4% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Unichem Laboratories?
As of 30 Jun 2026: promoters 70.22%, foreign institutions 0.90%, domestic institutions 10.46%, non-institutions 18.42%.
Who are Unichem Laboratories' competitors?
The listed Pharma & Healthcare companies closest to Unichem Laboratories by market cap are Gufic Biosciences, Gujarat Themis Biosyn, Aarti Drugs, Solara Active Pharma Sciences, Ind-Swift Laboratories and Advanced Enzyme Technologies.
Is Unichem Laboratories a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Unichem Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on UNICHEMLAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with U · all NSE stocks · this page as text